"The greatest wealth is health."         - Virgil

      Advertisement

Our Experts answered these questions:

My wife has arthritis,quite severe. if she sustains a bruise or a cut the results last for weeks or even months. she bruises badly with the slightest...
I was up last night having to use the bathroom with diarrhea for about an hour. This morning i woke up and i felt like i was going to throw up and i h...
Do You Have a Health Question? Ask Our Experts!

Vaccine Safety

Menu

• Home
• Ask our Experts about RENIVACE
• Ask Community about RENIVACE
• Read More Here
• Patients Wiki
• Share Your Health Story
• Take a Survey
• Health Blogs

More Resources

• Federal Food and Drug Administration
• Hospital Quality Reports
• Home Care Quality

RENIVACE Safety Questions, RENIVACE Answers

More Here>>Side Effects - FDA Reports 2006-2008

Medications A-Z:   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Welcome! Patientsville.com provides unique information about RENIVACE. Our extensive database of RENIVACE adverse events and RENIVACE warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.

>> Announcements

Check out our Hospital and Home Care Quality Reports.

Ask Our Health Experts about RENIVACE

Do You Have a Question about Your Health?

Our Doctors and Nurses will Help You Understand Your Symptoms and Feel Better!
Private, Confidential and Discreet

Type your question here

 letters left

RENIVACE Safety Reports

Total RENIVACE reports: 55.
RENIVACE FDA safety alerts: No.
Reported deaths: 4    Reported hospitalizations: 42.
Take RENIVACE Side Effects Survey or Share Your RENIVACE Story. Read More Here.

Physician from JAPAN reported RENIVACE problem on Dec 15, 2006. Male patient, 77 years of age, weighting 141.1 lb, was diagnosed with hypertension, thrombosis prophylaxis, diabetes mellitus non-insulin-dependent, gastric ulcer and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: acute myocardial infarction, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood immunoglobulin e increased, blood lactate dehydrogenase increased, c-reactive protein increased, interstitial lung disease, lymphocyte stimulation test positive. RENIVACE dosage: 5 MG QD PO. During the same period patient was treated with BUFFERIN, EUGLUCON, OMEPRAL, PANALDINE, DIOVAN. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Dec 20, 2006. Male patient, 66 years of age, was diagnosed with hypertension, gastrointestinal haemorrhage, hyperlipidaemia, coronary arterial stent insertion and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: acute myocardial infarction, blood pressure immeasurable, cardiac disorder, cardio-respiratory arrest, cardiogenic shock, coronary artery occlusion, coronary artery thrombosis, excoriation, gastrointestinal haemorrhage. RENIVACE dosage: 2.5 MG Q DAY PO. During the same period patient was treated with GASTER D, LIPITOR, ASPIRIN, PLAVIX, SIGMART, LUPRAC, ARTIST. Patient was hospitalized. Patient died on 10/31/2006.

Physician from JAPAN reported RENIVACE problem on Dec 18, 2006. Male patient, 82 years of age, was diagnosed with hypertension, stent placement, arteriogram, angina pectoris and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: pharyngeal oedema, respiratory disorder, respiratory distress, snoring, stridor. RENIVACE dosage: 1.25 MG BID PO. During the same period patient was treated with PLETAL, IOMERON, NITOROL, PANALDINE, ASPIRIN, AMLODIPINE BESYLATE, TAMBOCOR. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Dec 21, 2006. Male patient, 93 years of age, weighting 79.37 lb, was diagnosed with cardiac failure congestive and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: inappropriate antidiuretic hormone secretion, large intestinal haemorrhage, melaena, ulcer haemorrhage. RENIVACE dosage: 5 MG BID PO. During the same period patient was treated with ASPIRIN, GASTROM, GASPORT, NITRODERM, LACTEC, SOLITA, PURSENNID. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Jan 24, 2007. Male patient, 65 years of age, was diagnosed with cardiac failure and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: blood immunoglobulin e increased, erythema, rash papular. RENIVACE dosage: 5 MG QD PO. During the same period patient was treated with NU LOTAN, ALDACTONE, LUPRAC, SPELEAR, HUSTAZOL, CLARITHROMYCIN, TAKEPRON, BAKTAR. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Pharmacist from JAPAN on Feb 08, 2007. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: deafness, myocardial infarction. RENIVACE dosage: unknown. Patient was hospitalized. Patient recovered.

Pharmacist from JAPAN reported RENIVACE problem on Feb 21, 2007. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: accidental exposure, accidental overdose, diarrhoea. RENIVACE dosage: 300 MG ONCE PO. Patient recovered.

RENIVACE problem was reported by a Health Professional from JAPAN on Feb 27, 2007. Female patient, 82 years of age, was diagnosed with cardiac failure, angina pectoris and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: eczema. RENIVACE dosage: 2.5 MG QD PO. During the same period patient was treated with ITOROL, ETODOLAC, ACTONEL, LOXONIN, MUCOSTA, OSTEN, CELGOTIN. Patient recovered.

Pharmacist from JAPAN reported RENIVACE problem on Mar 13, 2007. Male patient, 74 years of age, was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cardiac failure, condition aggravated, overdose. RENIVACE dosage: 10 MG BID PO. During the same period patient was treated with WARFARIN, HALFDIGOXIN, MEVALOTIN, PLETAL. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Pharmacist from JAPAN on Apr 05, 2007. Male patient, 74 years of age, was diagnosed with cardiac failure and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cardiac failure, condition aggravated, overdose. RENIVACE dosage: (10 MG BID ORAL). During the same period patient was treated with ENALAPRIL MALEATE, WARFARIN, DIGOXIN, MEVALOTIN, PLETAL. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Apr 11, 2007. Female patient was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: lymphocyte stimulation test positive, pustular psoriasis. RENIVACE dosage: unknown. During the same period patient was treated with BLOPRESS. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Pharmacist from JAPAN on May 07, 2007. Male patient, 50 years of age, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: fall, head injury, hypersomnia, loss of consciousness, skin laceration. RENIVACE dosage: (5 MG QD ORAL). During the same period patient was treated with ENALAPRIL MALEATE, CONIEL, XALATAN. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on May 18, 2007. Male patient, 61 years of age, was diagnosed with hypertension, arrhythmia, angina pectoris and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cardiac disorder, liver function test abnormal. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with BAYASPIRIN, SELOKEN, SIGMART, FRANDOL, BAYLOTENSIN. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Consumer or non-health professional from JAPAN on May 21, 2007. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: dizziness, overdose, treatment noncompliance. RENIVACE dosage: unknown. During the same period patient was treated with TIMOPTOL. Patient recovered.

Physician from JAPAN reported RENIVACE problem on June 13, 2007. Male patient, 61 years of age, was diagnosed with hypertension, arrhythmia and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cardiac disorder, liver function test abnormal. RENIVACE dosage: 2.5 MG QD ORAL. During the same period patient was treated with BAYASPIRIN, SELOKEN, SIGMART. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Pharmacist from JAPAN on June 19, 2006. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: accidental overdose, no adverse effect. RENIVACE dosage: 15 MG ONCE PO. Patient recovered.

Physician from JAPAN reported RENIVACE problem on June 21, 2006. Female patient, 79 years of age, weighting 132.3 lb, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: angioneurotic oedema, depressed level of consciousness, dysarthria, laboratory test abnormal, oropharyngeal swelling, pharyngeal stenosis, pharyngolaryngeal pain, respiratory arrest. RENIVACE dosage: 5 MG QAM PO. During the same period patient was treated with UNIPHYL, LORAZEPAM, SEPAMIT, ONION, GASTER D, LASIX, ZYRTEC, FLUTIDE. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on June 21, 2006. Male patient, 53 years of age, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, angioneurotic oedema, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, disease recurrence, dysphonia, eosinophil percentage decreased, face oedema. RENIVACE dosage: 5 MG QD PO. During the same period patient was treated with ASPIRIN, MARZULENE S, DILTIAZEM. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on June 26, 2006. Male patient was diagnosed with cardiac failure and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: liver disorder, lymphocyte stimulation test positive. RENIVACE dosage: 5 MG QD PO. During the same period patient was treated with ASPIRIN, PANALDINE, LIVALO, SIGMART. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on July 06, 2006. Female patient, 79 years of age, weighting 132.3 lb, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: angioneurotic oedema, depressed level of consciousness, dyspnoea, laboratory test abnormal, pharyngeal stenosis, pharyngolaryngeal pain, respiratory arrest, tonsillar disorder. RENIVACE dosage: 5 MG QAM PO. During the same period patient was treated with UNIPHYL, LORAZEPAM, SEPAMIT, ONION, GASTER D, LASIX, ZYRTEC, FLUTIDE. Patient was hospitalized. Patient recovered.

Physician from ALBANIA reported RENIVACE problem on July 31, 2006. Male patient, 70 years of age, weighting 149.9 lb, was diagnosed with hypertension, angina pectoris, coronary arterial stent insertion, hyperlipidaemia, hypertonia and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, gamma-glutamyltransferase increased, liver disorder, lymphocyte stimulation test, lymphocyte stimulation test positive. RENIVACE dosage: 5 MG Q DAY PO. During the same period patient was treated with PANALDINE, LIVALO, SIGMART, CALBLOCK, ARTIST. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Aug 23, 2006. Male patient, 70 years of age, weighting 149.9 lb, was diagnosed with hypertension, angina pectoris, coronary arterial stent insertion, hyperlipidaemia, hypertonia and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased, liver disorder, lymphocyte stimulation test positive. RENIVACE dosage: 5 MG Q DAY PO. During the same period patient was treated with PANALDINE, LIVALO, SIGMART, CALBLOCK, ARTIST. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Sept 05, 2006. Female patient, child 9 years of age, weighting 55.12 lb, was diagnosed with renal hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: nephritis interstitial, renal failure. RENIVACE dosage: 5 MG QD PO. During the same period patient was treated with PASETOCIN, ADALAT. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Sept 29, 2006. Male patient, 75 years of age, was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: depressed level of consciousness, hypoglycaemia. RENIVACE dosage: unknown. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Sept 28, 2006. Male patient, 75 years of age, weighting 90.39 lb, was diagnosed with cardiac failure and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cardiac failure, condition aggravated, gait disturbance, impetigo, nasopharyngitis, pemphigoid, spinal compression fracture. RENIVACE dosage: 2.5 MG BID PO. During the same period patient was treated with AMLODIN, LASIX, GASTER D, CLARITIN, FEXOFENADINE, DIFLUPREDNATE. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Oct 06, 2006. Female patient, 43 years of age, was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: blood glucose fluctuation, depressed level of consciousness, intentional overdose, suicide attempt. RENIVACE dosage: 100 MG ONCE PO. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Oct 10, 2006. Female patient, 80 years of age, was diagnosed with cardiac failure, hypertension, hyperuricaemia, constipation and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased, stevens-johnson syndrome, white blood cell count decreased. RENIVACE dosage: 5 MG QD PO. During the same period patient was treated with ALLOPURINOL, ADALAT, PURSENNID, LASIX. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Oct 13, 2006. Male patient, 73 years of age, weighting 163.1 lb, was diagnosed with hypertension, gastric ulcer, gastric ulcer haemorrhage, sepsis, angina pectoris, myocardial infarction and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gastric ulcer haemorrhage, hepatic infiltration eosinophilic, liver disorder. RENIVACE dosage: 2.5 MG BID PO. During the same period patient was treated with FAMOTIDINE, GASTER D, PAZUCROSS, PANALDINE, ARTIST, ASPIRIN, SIGMART. Patient was hospitalized. Patient recovered.

Pharmacist from JAPAN reported RENIVACE problem on Oct 17, 2006. Female patient was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, asthenia, blood lactate dehydrogenase increased, chromaturia, gamma-glutamyltransferase increased, hepatic function abnormal. RENIVACE dosage: 2.5 MG Q DAY PO. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Nov 06, 2006. Male patient, 66 years of age, was diagnosed with hypertension, gastrointestinal haemorrhage, hyperlipidaemia, coronary arterial stent insertion and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: atrial fibrillation, blister, cardiac disorder, cardio-respiratory arrest, cardiogenic shock, erythema, excoriation, gastrointestinal haemorrhage. RENIVACE dosage: 2.5 MG Q DAY PO. During the same period patient was treated with GASTER D, LIPITOR, ASPIRIN, PLAVIX, SIGMART, LUPRAC, ARTIST. Patient was hospitalized. Patient died on 10/31/2006.

Physician from JAPAN reported RENIVACE problem on Nov 07, 2006. Male patient, 73 years of age, weighting 163.1 lb, was diagnosed with myocardial infarction, gastric ulcer haemorrhage, sepsis and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, chills, cholelithiasis, gamma-glutamyltransferase increased, hepatic infiltration eosinophilic, liver disorder, pyrexia. RENIVACE dosage: 2.5 MG BID PO. During the same period patient was treated with GASTER, GASTER D, PAZUCROSS, PANALDINE, ARTIST, ASPIRIN, SIGMART. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Nov 14, 2006. Male patient, 66 years of age, was diagnosed with hypertension, gastrointestinal haemorrhage, hyperlipidaemia, coronary arterial stent insertion and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: acute myocardial infarction, apparent life threatening event, blood pressure immeasurable, cardiac disorder, cardio-respiratory arrest, condition aggravated, gastrointestinal haemorrhage, pyrexia, skin haemorrhage. RENIVACE dosage: 2.5 MG Q DAY; PO. During the same period patient was treated with GASTER D, LIPITOR, ASPIRIN, PLAVIX, SIGMART, LUPRAC, ARTIST. Patient was hospitalized. Patient died on 10/31/2006.

Health Professional from JAPAN reported RENIVACE problem on Nov 20, 2006. Male patient, 82 years of age, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: pharyngeal oedema, respiratory distress. RENIVACE dosage: 1.25 MG BID PO. During the same period patient was treated with PANALDINE, LIVALO, ASPIRIN, AMLODIPINE BESYLATE, TAKEPRON. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Nov 21, 2006. Male patient, 77 years of age, was diagnosed with hypertension, prophylaxis, thrombosis prophylaxis and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: interstitial lung disease. RENIVACE dosage: 2.5 MG Q DAY PO. During the same period patient was treated with DIOVAN, EUGLUCON, OMEPRAL, PANALDINE. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Nov 28, 2006. Male patient, 82 years of age, weighting 70.55 lb, was diagnosed with myocardial infarction and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, cardio-respiratory arrest, eosinophilia, gastrointestinal haemorrhage, white blood cell count increased. RENIVACE dosage: 2.5 MG QD PO. During the same period patient was treated with ASPIRIN, PANALDINE, MAGNESIUM OXIDE, SIGMART, ARTIST, LUPRAC, LASIX, FLUITRAN. Patient died on 11/19/2006.

RENIVACE problem was reported by a Consumer or non-health professional from AMERICAN SAMOA on Dec 01, 2006. Male patient, 82 years of age, was diagnosed with hypertension, stent placement, arteriogram, angina pectoris and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: bronchostenosis, dyspnoea, laryngeal oedema, pharyngeal oedema, respiratory distress, snoring, stridor. RENIVACE dosage: 1.25 MG BID PO. During the same period patient was treated with PLETAL, IOMERON, NITOROL, PANALDINE, ASPIRIN, AMLODIPINE BESYLATE, TAMBOCOR. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Dec 04, 2006. Male patient, 93 years of age, weighting 79.37 lb, was diagnosed with cardiac failure congestive and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: inappropriate antidiuretic hormone secretion, large intestinal haemorrhage, ulcer. RENIVACE dosage: 5 MG BID PO. During the same period patient was treated with ASPIRIN, GASTROM, GASPORT, PURSENNID, NITRODERM, LACTEC, SOLITA. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on June 20, 2007. Female patient, 62 years of age, weighting 99.21 lb, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: aortic valve stenosis, chest discomfort, condition aggravated, dyspnoea exertional, post procedural complication, swollen tongue. RENIVACE dosage: unknown. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on June 21, 2007. Male patient, 61 years of age, was diagnosed with hypertension, arrhythmia, angina pectoris and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cardiac disorder, liver function test abnormal. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with ACETYLSALICYLIC ACID SRT, SELOKEN, SIGMART, FRANDOL, BAYLOTENSIN. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on June 28, 2007. Male patient, 70 years of age, weighting 154.3 lb, was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: interstitial lung disease. RENIVACE dosage: 5 MG QD ORAL. During the same period patient was treated with TAKEPRON, ARTIST, LASIX, GRAMALIL, ASPIRIN, TICLOPIDINE, DEPAS, AMLODIPINE. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on July 03, 2007. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: cough, liver disorder, nephrotic syndrome. RENIVACE dosage: (10 MG QD ORAL), (5 MG QD ORAL). Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on July 04, 2007. Male patient, 56 years of age, was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: hepatic function abnormal, pyrexia, toxic skin eruption. RENIVACE dosage: 1.25 MG QD ORAL. During the same period patient was treated with PANALDINE, VOGLIBOSE, TAKEPRON, HALCION, SIGMART, ALPRAZOLAM, ASPIRIN, METOPROLOL TARTRATE. Patient was hospitalized. Patient recovered.

Physician from JAPAN reported RENIVACE problem on July 10, 2007. Male patient, 39 years of age, weighting 198.4 lb, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: chest pain. RENIVACE dosage: (5 MG QD ORAL). During the same period patient was treated with HYDROCHLOROTHIAZIDE W. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on July 11, 2007. Male patient, 70 years of age, was diagnosed with cardiac failure and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, leukopenia. RENIVACE dosage: 2.5 MG QD ORAL. During the same period patient was treated with EPALRESTAT, LASIX. Patient was hospitalized. Patient recovered.

Pharmacist from JAPAN reported RENIVACE problem on July 18, 2007. Female patient was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: activities of daily living impaired, faecal incontinence. RENIVACE dosage: 5 MG QD ORAL. During the same period patient was treated with BONALON, ASPARA, SENNA, ASPIRIN, DEKASOFT, URSO, REBAMIPIDE, OMEPRAL. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Pharmacist from JAPAN on July 23, 2007. Female patient was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alopecia, pneumothorax. RENIVACE dosage: 2.5 MG QD ORAL. Patient recovered.

Consumer or non-health professional from JAPAN reported RENIVACE problem on July 25, 2007. Male patient, 70 years of age, weighting 198.4 lb, was diagnosed with cardiac failure, diabetic neuropathy and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, hypokalaemia, leukopenia, neutrophil count decreased. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with EPALRESTAT, ALDACTONE, ARTIST, DIGOSIN, LASIX, WARFARIN POTASSIUM. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on July 31, 2007. Male patient, 56 years of age, weighting 156.5 lb, was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: hepatic function abnormal, pyrexia, toxic skin eruption. RENIVACE dosage: (1.25 MG QD ORAL). During the same period patient was treated with PANALDINE, VOGLIBOSE, TAKEPRON, HALCION, SIGMART, ALPRAZOLAM, ASPIRIN, METOPROLOL TARTRATE. Patient was hospitalized. Patient recovered.

Pharmacist from JAPAN reported RENIVACE problem on Aug 01, 2007. Female patient, 81 years of age, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: asthenia, condition aggravated, faecal incontinence. RENIVACE dosage: (5 MG ORAL). During the same period patient was treated with BONALON, ASPARA, SENNA, ASPIRIN, DEKASOFT, URSO, REBAMIPIDE, OMEPRAL. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Aug 02, 2007. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, cholangitis, lymphocyte count decreased, neutrophil count increased, oxygen saturation decreased, rhabdomyolysis, sneezing, vomiting. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with GASTER D, ZYLORIC, NORVASC, BICARBONATE, LIPITOR, THYRADIN, LUPRAC, CINAL. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Aug 16, 2007. Female patient, 76 years of age, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: interstitial lung disease, lymphocyte stimulation test positive. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with NORVASC, PRAVASTATIN, OMEPRAZOLE. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Aug 17, 2007. Male patient, 39 years of age, weighting 198.4 lb, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: blood pressure inadequately controlled, chest pain, electrocardiogram st-t change, headache, palpitations. RENIVACE dosage: 5 MG QD ORAL. During the same period patient was treated with HYDROCHLOROTHIAZIDE W. Patient recovered.

Physician from JAPAN reported RENIVACE problem on Aug 20, 2007. Male patient, 70 years of age, weighting 198.4 lb, was diagnosed with cardiac failure, diabetic neuropathy and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, diabetic neuropathy, granulocytopenia, hepatic enzyme increased, hypokalaemia, leukopenia, monocyte percentage increased, neutrophil percentage decreased. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with EPALRESTAT, SPIRONOLACTONE, ALDACTONE, ARTIST, DIGOSIN, LASIX, WARFARIN POTASSIUM. Patient was hospitalized. Patient recovered.

RENIVACE problem was reported by a Physician from JAPAN on Aug 27, 2007. Female patient, 42 years of age, weighting 114.6 lb, was diagnosed with hypertension and was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: abasia, c-reactive protein increased, erythema, pain. RENIVACE dosage: (2.5 MG QD ORAL). During the same period patient was treated with ANPLAG, ASPIRIN, DIART, JUVELA, LIPITOR, NEORAL, PREDONINE. Patient was hospitalized. Patient recovered.

Health Professional from JAPAN reported RENIVACE problem on Sept 11, 2007. Female patient was treated with RENIVACE. After drug was administered, patient experienced the following problems/side effects: systemic lupus erythematosus. RENIVACE dosage: 5 MG QD ORAL. During the same period patient was treated with PANALDINE. Patient recovered.

Ask Our Patient Community about RENIVACE
Select a Medication and Click to Access Reports about Side Effects and Adverse Reactions
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z
This drug has an active FDA Safety Alert
A Abacavir sulfate Abatacept Abilify Acamprosate calcium Accupril Accutane Aceon Aciphex Actiq (fentanyl citrate) Actimmune (aripiprazole) (quinapril) (isotretinoin) (perindopril) (rabeprazole) (interferon gamma-1b) Actonel (risedronate) Actoplus Met (pioglitazone) Actos (pioglitazone) AcuTect (technetium Tc 99m apcitide) Adefovir dipivoxil Advair Diskus(Fluticasone propionate; Salmeterol xinafoate) Adderall (amphetamine salts) Agenerase (amprenavir) Aggrastat (tirofiban) Alamast (pemirolast) Alendronate Alemtuzumab Aleve (naproxen sodium) Alfuzosin Alinia (nitazoxanide) Alimta (pemetrexed) Alitretinoin Almotriptan malate Alosetron hydrochloride Aloxi (palonosetron) Alrex (loteprednol etabonate) Altace (ramipril) Ambien (zolpidem tartrate) Amerge (naratriptan) Aminolevulinic acid Amiodarone Amitiza (lubiprostone) Amnesteem (isotretinoin) Amphadase (hyaluronidase) luronidase) Amphetamine salts Amprenavir Anaprox (naproxen sodium) Angiomax (bivalirudin) Anidulafungin Antagon (ganirelix acetate) Anthelios SX (avobenzone, ecamsule, octocrylene) Apidra (insulin glulisine recombinant) Apokyn (apomorphine) Aprepitant Aprotinin Aptivus (tipranavir) Aranesp (darbepoetin alpha) Arava (leflunomide) Arformoterol Argatroban Aredia (pamidronate) Aripiprazole Arixtra (fondaparinux) Aromasin (exemestane) Arranon (nelarabine) Arsenic trioxide Aspirin Atacand (candesartan cilexetil) Atazanavir sulfate Atomoxetine Avastin (bevacizumab) Avelox (moxifloxacin) Avobenzone, Ecamsule, Octocrylene Avodart (dutasteride) Avonex (interferon beta-1a) Axert (almotriptan malate) Azacitidine Azilect (rasagiline) Azopt (brinzolamide) back to top B Balsalazide disodium Baraclude (entecavir) Benazepril Benicar (olmesartan medoxomil) Bevacizumab Bexarotene Bextra (valdecoxib) Biaxin (clarithromycin) Bimatoprost Bivalirudin Boniva (ibandronate) Bortezomib Brinzolamide Brovana (arformoterol) Bupropion Butisol sodium Byetta (exenatide) back to top C Calfactant Campath (alemtuzumab) Campral (acamprosate calcium) Cancidas (caspofungin) Candesartan cilexetil Capecitabine Capoten (captopril) Captopril Carbamazepine Carbatrol (carbamazepine) Carbrital (pentobarbital and carbromal) Caspofungin Cefditoren pivoxil Cefepime Ceftriaxone Celebrex (celecoxib) Celecoxib Celexa (citalopram hydrobromide) Cetrorelix acetate Cetrotide (cetrorelix acetate) Cetuximab Cevimeline Chantix (varenicline) Cialis (tadalafil) Cilostazol Cinacalcet Cirlesonide Citalopram Claravis (isotretinoin) Clarithromycin Clarinex (desloratadine) Clolar (clofarabine) Clofarabine Clozapine Clozaril (clozapine) Codeine Colazal (balsalazide disodium) Colesevelam Colistimethate Coly-Mycin M (colistimethate) Comtan (entacapone) Concerta (methylphenidate) Conivaptan Cordarone (amiodarone) Crestor (rosuvastatin calcium) Cubicin (daptomycin) Curosurf (poractant alfa) Cylert (pemoline) Cymbalta (duloxetine) Cytotec (misoprostol) back to top D Dacogen (decitabine) Dalfopristin Dalmane (flurazepam) Daptomycin Darbepoetin alpha Darifenacin Darunavir Dasatinib Daytrana (methylphenidate transdermal) DDAVP (desmopressin) DDAVP Nasal Spray (demopressin) DDAVP Rhinal Tube (desmopressin) DDVP (desmopressin Decitabine Deferasirox Definity (perflutren lipid microspheres) Depacon (valproate) Depakene (valproate) Depakote (valproate) Desloratadine Desmopressin Detrol (tolterodine tartrate) terodine tartrate) Dexedrine (dextroamphetamine sulfate) Dexmedetomidine Dexmethylphenidate HCl > Dextroamphetamine sulfate Diastat AcuDial Diazepam rectal gel Didronel (etidronate) Diprivan (propofol) Dofetilide Doral (quazepam) Doxercalcif Drospirenone Duloxetine Duragesic (fentanyl transdermal system) Dutasteride back to top E Eculizumab Edetate disodium Efalizumab Efavirenz Effexor (venlafaxine) Elestat (epinastine) Eletriptan Elidel (pimecrolimus) Ellence (epirubicin) Eloxatin (oxaliplatin) Emend (aprepitant) Emtricitabine Emtriva (emtricitabine) Enablex (darifenacin) Enalapril / Enalaprilat Endrate (edetate disodium) Enfuvirtide Entacapone Entecavir Epinastine Epirubicin Eplerenone Epoetin alfa Epogen (epoetin alfa) Eptifibatide Equetro (carbamazepine) Eraxis (anidulafungin) Erbitux (cetuximab) Ertaczo (sertaconazole) Escitalopram Estazolam Eszopiclone Ethchlorvynol Ethinyl estradiol Etidronate Evoxac (cevimeline) Exelon (rivastigmine tartrate) Exenatide Exjade (deferasirox) Exemestane Extraneal (icodextrin) Ezetimibe Ezetimibe/simvastatin back to top	F Factive (gemifloxacin mesylate) Faslodex (fulvestrant) Felbamate Felbatol (felbamate) Fentanyl buccal tablets Fentanyl citrate Fentanyl transdermal system Fentora (fentanyl buccal tablets) Ferrlecit (sodium ferric gluconate complex) Fleet Accu-Prep (sodium phosphate) Fleet Phospho-Soda (sodium phosphate) Fluoxetine Flurazepam Fluticasone propionate Fluvoxamine Focalin (dexmethylphenidate) Focalin XR (dexmethylphenidate) Fomivirsen Fondaparinux Foradil (formoterol fumarate) Formoterol fumarate Fosamax (alendronate) Fosinopril Frova (frovatriptan succinate) Frovatriptan succinate Fulvestrant Fuzeon (enfuvirtide) G Gabapentin Gabitril (tiagabine) Gadobenate Dimeglumine Gadodiamide Gadolinium Gadopentetate Dimeglumine Gadoteridol Gadoversetamide Galantamine Ganirelix acetate Gatifloxacin Gefitinib Gemifloxacin mesylate Gemtuzumab ozogamicin Geodon (ziprasidone) Gleevec (imatinib mesylate) back to top H Halcion (triazolam) Haldol (haloperidol) Haloperidol Hectorol (doxercalcif) Hepsera (adefovir dipivoxil) Hyaluronidase Hydase (hyaluronidase) Human Secretin back to top I Ibandronate Ibuprofen Icodextrin Iloprost Imatinib mesylate Increlex (Mecasermin [rDNA origin] Infasurf Preservative Free (calfactant) Imitrex (sumatriptan) Innohep (tinzaparin) Inspra (eplerenone) Insulin Aspart recombinant Insulin Detemir recombinant Insulin Glargine recombinant Insulin Glulisine recombinant Intron A (interferon alfa-2b) Integrilin (eptifibatide) ifibatide) Interferon alfa-2b Interferon beta-1a Interferon gamma-1b Invega (paliperidone) Iplex  (mecasermin rinfabate) Iressa (gefitinib) Isotretinoin back to top J Januvia (sitagliptin phosphate) back to top K Kaletra (lopinavir; ritonavir) Kepivance (palifermin) Keppra (levetiracetam) Ketek (telithromycin) Ketotifen fumarate back to top L Lamictal (lamotrigine) Lamotrigine Lantus (insulin glargine recombinant) Leflunomide Lenalidomide Lepirudin recombinant Levalbuterol Levemir (insulin detemir recombinant) Levetiracetam Levitra (vardenafil) Levonorgestrel Levothyroxine sodium Levulan Kerastick (aminolevulinic acid) Lexapro (escitalopram) Lindane Linezolid Lisinopril Lopinavir/ritonavir Lotemax (loteprednol etabonate) Lotensin (benazepril) Loteprednol etabonate Lotronex (alosetron hydrochloride) Lubiprostone Lucentis (ranibizumab) Lumigan (bimatoprost) Lunestra (eszopiclone) Lyrica (pregabalin) back to top M Macugen (pegaptanib) Magnevist (gadopentetate dimeglumine) Maraviroc Mavik (trandolapril) Maxalt (rizatriptan benzoate) Maxipime (cefepime) Mecasermin [rDNA origin] Mecasermin-rinfabate Meloxicam Memantine Metadate CD (methylphenidate HCl) ylphenidate HCl) Methylphenidate HCl Methylphenidate transdermal Mequinol Micafungin Micardis (telmisartan) misartan) Mifeprex (mifepristone) Mifepristone Miglustat Minirin (desmopressin) Mirtazapine Misoprostol Mobic (meloxicam) Modafinil Moexipril Monopril (fosinopril) Moxifloxacin MultiHance (gadobenate dimeglumine) Mycamine (micafungin) Mylotarg (gemtuzumab ozogamicin) back to top N Namenda (memantine) Naprosyn (naproxen) Naproxen Naratriptan Nesiritide recombinant Nateglinide Natrecor (nesiritide recombinant) Nefazodone Nelarabine NeoTect Kit (technetium Tc 99m depreotide) Nesiritide recombinant Neurontin (gabapentin) Nexavar (sorafenib) Nitazoxanide Nitisinone Norelgestromin NovoLog (insulin aspart recombinant) Noxafil (posaconazole) back to top O Olanzapine Olanzapine/fluoxetine Olmesartan medoxomil Omacor (omega-3-acid ethyl esters) Omalizumab Omega-3-acid ethyl esters Omnaris (cirlesonide) Omniscan (gadodiamide) OptiMARK (gadoversetamide) Optison (perflutren protein-type A microspheres) Orencia (abatacept) Orfadin (nitisinone) Orlistat Ortho Evra (norelgestromin; ethinyl estradiol) Oseltamivir phosphate Osmoprep (sodium phosphate) Oxaliplatin Oxcarbazepine back to top P Pacerone (amiodarone) Palifermin Paliperidone Pamidronate Panitumumab Panretin Gel (alitretinoin) Pantoprazole Paricalcitol Paroxetine Paxil (paroxetine) Pegaptanib Pegvisomant Pemetrexed Pemoline Pentobarbital and carbromal Perflutren lipid microspheres Perindopril Phenergan (promethazine) Pimecrolimus Pioglitazone Placidyl (ethchlorvynol) Plan B (levonorgestrel) Pletal (cilostazol) Poractant alfa Posaconazole Pramlintide Acetate Precedex (dexmedetomidine) Pregabalin Prezista (darunavir) Prialt (ziconotide) Priftin (rifapentine) Prinivil (lisinopril) Procrit